| JNJ | Johnson & Johnson | 10.24% |
| LLY | Eli Lilly and Co | 7.55% |
| ABBV | AbbVie Inc | 6.08% |
| MRK | Merck & Co Inc | 5.77% |
| BMY | Bristol-Myers Squibb Co | 5.36% |
| VRTX | Vertex Pharmaceuticals Inc | 5.13% |
| AMGN | Amgen Inc | 4.38% |
| MRNA | Moderna Inc | 4.33% |
| GILD | Gilead Sciences Inc | 4.01% |
| REGN | Regeneron Pharmaceuticals Inc | 3.96% |
The fund invests, under normal circumstances, at least 80% of its net assets in U.S. listed common stock of large-, mid- and small-capitalization pharmaceutical and biotechnology companies. It will hold common stock of those companies that fall into the Innovative Healthcare Evolved Sector which have economic characteristics that have been historically correlated with companies traditionally defined as pharmaceutical and biotechnology companies. The fund is non-diversified.
iShares Evolved U.S. Innovative Healthcare ETF · Issued by IShares
No recent news for IEIH. The ingest cron pulls every 15 minutes during market hours.